Get the Stockscreener App
10.59
4.34%
-0.48
After Hours:
10.92
0.33
+3.12%
Mink Therapeutics Inc stock is traded at $10.59, with a volume of 9,656.
It is down -4.34% in the last 24 hours and down -9.02% over the past month.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development and manufacturing of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells offer distinct therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of tumors and infected cells, and suppress graft-versus-host-disease. Its product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy. It operates its business in single segment.
See More
Previous Close:
$11.07
Open:
$11.25
24h Volume:
9,656
Relative Volume:
0.34
Market Cap:
$52.76M
Revenue:
-
Net Income/Loss:
$-12.49M
P/E Ratio:
-3.5719
EPS:
-2.9648
Net Cash Flow:
$-5.93M
1W Performance:
-1.67%
1M Performance:
-9.02%
6M Performance:
-17.46%
1Y Performance:
-42.94%
1-Day Range:
$10.50
$11.25
1-Week Range:
$10.21
$11.30
52-Week Range:
$8.4801
$19.61
Mink Therapeutics Inc Stock (INKT) Company Profile
Name
Mink Therapeutics Inc
Sector
Industry
Phone
212-994-8250
Address
149 FIFTH AVENUE, NEW YORK
Compare INKT vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INKT
Mink Therapeutics Inc
|
10.59 | 55.15M | 0 | -12.49M | -5.93M | -2.9648 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Mink Therapeutics Inc Stock (INKT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-15-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jul-14-25 | Downgrade | William Blair | Outperform → Mkt Perform |
Mink Therapeutics Inc Stock (INKT) Latest News
Mink Therapeutics Inc (INKT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Mink Therapeutics Inc (INKT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Mink Therapeutics Inc (INKT) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
INKT|Mink Therapeutics Inc|Price:11.070|Chg%:+0.700 - TradingKey
TradingKey - TradingKey
MiNK Therapeutics, Inc. Revenue Breakdown – FWB:6Q40 - TradingView
Mink Therapeutics Inc (INKT) Valuation: PE, PB & Fair Value Analysis - TradingKey
Mink Therapeutics Inc (INKT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
MiNK Therapeutics, Inc. Revenue Breakdown – MUN:6Q40 - TradingView
INKT|Mink Therapeutics Inc|Price:11.240|Chg%:+0.880 - TradingKey
INKT|Mink Therapeutics Inc|Price:10.780|Chg%:-0.290 - TradingKey
INKT|Mink Therapeutics Inc|Price:11.380|Chg%:+0.310 - TradingKey
Mink Therapeutics Inc (INKT) Institutional Confidence - TradingKey
Here's why you should add INKT stock to your portfolio now - MSN
Here's Why You Should Add INKT Stock to Your Portfolio Now - TradingView
What date does MiNK Therapeutics, Inc.'s (INKT) report EarningsEarnings Calendar & Announcement - Zacks Investment Research
Why (INKT) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Mink Therapeutics (INKT) Proxy filing Summary - Quartr
Mink Therapeutics (INKT) H.C. Wainwright 26th Annual Global Investment Conference 2024 summary - Quartr
Mink Therapeutics (INKT) Q1 2025 earnings summary - Quartr
Cost of goods sold of MiNK Therapeutics, Inc. – DUS:6Q40 - TradingView
Understanding Momentum Shifts in (INKT) - Stock Traders Daily
MiNK Therapeutics, Inc.(NasdaqCM:INKT) added to Russell Microcap Value Benchmark Index - marketscreener.com
MiNK Therapeutics, Inc.(NasdaqCM:INKT) added to Russell Microcap Growth Benchmark Index - marketscreener.com
MiNK Therapeutics, Inc.(NasdaqCM: INKT) added to Russell 3000E Growth Benchmark - marketscreener.com
MiNK Therapeutics, Inc.(NasdaqCM: INKT) added to Russell Microcap Index - marketscreener.com
MiNK Therapeutics, Inc.(NasdaqCM: INKT) added to Russell 3000E Value Benchmark - marketscreener.com
MiNK Therapeutics Advances Phase 2 Trial of agenT-797 in Severe Pneumonia: What Investors Should Watch - TipRanks
Enterprise value to EBITDA forward of MiNK Therapeutics, Inc. – NASDAQ:INKT - TradingView
MiNK Therapeutics, Inc. Actuals & Estimates (NASDAQ:INKT) - TradingView
Price to earnings forward of MiNK Therapeutics, Inc. – NASDAQ:INKT - TradingView
Price to sales forward of MiNK Therapeutics, Inc. – NASDAQ:INKT - TradingView
INKT Forecast — Price Target — Prediction for 2027 - TradingView
MiNK Therapeutics Stockholders Back Directors, Ratify Auditor - The Globe and Mail
Total liabilities & shareholders' equities of MiNK Therapeutics, Inc. – DUS:6Q40 - TradingView
Form 8K Mink Therapeutics Inc For: 23 June By Investing.com - Investing.com South Africa
MiNK Therapeutics (INKT) investors reelect board members and ratify KPMG at 2026 meeting - Stock Titan
MiNK Therapeutics (INKT) Edges Higher, Approaching Key Resistance at $12.88Liquidity Sweep - dars.gov.et
Avoiding Lag: Real-Time Signals in (INKT) Movement - Stock Traders Daily
Inventory turnover of MiNK Therapeutics, Inc. – DUS:6Q40 - TradingView
Diluted net income available to common stockholders of MiNK Therapeutics, Inc. – DUS:6Q40 - TradingView
After tax other income/expense of MiNK Therapeutics, Inc. – DUS:6Q40 - TradingView
Book value per share of MiNK Therapeutics, Inc. – DUS:6Q40 - TradingView
MiNK Therapeutics, Inc. Cash Flow – DUS:6Q40 - TradingView
Debt to equity ratio of MiNK Therapeutics, Inc. – DUS:6Q40 - TradingView
Mink Therapeutics Inc (INKT) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Mink Therapeutics Inc (INKT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Mink Therapeutics (INKT) Q1 2026 earnings summary - Quartr
Mink Therapeutics (INKT) AGM 2026 Summary - Quartr
INKT: Directors and auditor elected, immune restoration strategy advanced, and global trials expanded - TradingView
Mink Therapeutics Inc (INKT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Mink Therapeutics Inc Stock (INKT) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.97%
0.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):